Published in AIDS Weekly, August 14th, 1995
Additional data from the study, first reported in the March 1995 Journal of AIDS, were presented at the International Symposium on Clinical Immunology, held July 20-23, 1995 in San Francisco, California.
The 48 week placebo controlled double-blind study, conducted by T.C. Merigan and colleagues at California's Stanford University, demonstrated that thymopentin (TP5) delayed disease progression to AIDS. Additional analyses assessed which subjects at study entry are...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.